PATH vs PAVM · P/E 19, rev $1.61B vs rev $3.0M
Uipath Inc (PATH) versus PAVmed Inc (PAVM) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
PAVmed Inc (PAVM) is a medical devices company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PAVM revenue for 2024-12-31 was $3.0M. Net income was $28.4M. Revenue was up 20.0% from 2023-12-31 to 2024-12-31. PAVM currently screens at market cap $35.7M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PAVM currently screens at market cap $35.7M.
Not investment advice. Open the PATH and PAVM stock pages for the full models.
Not investment advice.